Candel Therapeutics, Inc. (CADL)
11.47
-0.70
(-5.75%)
USD |
NASDAQ |
Sep 10, 13:28
Candel Therapeutics Total Liabilities (Quarterly) : 82.02M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.02M |
| March 31, 2026 | 63.89M |
| December 31, 2025 | 73.71M |
| September 30, 2025 | 13.47M |
| June 30, 2025 | 15.76M |
| March 31, 2025 | 21.23M |
| December 31, 2024 | 40.82M |
| September 30, 2024 | 36.77M |
| June 30, 2024 | 36.46M |
| March 31, 2024 | 25.24M |
| December 31, 2023 | 28.96M |
| September 30, 2023 | 27.04M |
| Date | Value |
|---|---|
| June 30, 2023 | 27.94M |
| March 31, 2023 | 27.59M |
| December 31, 2022 | 30.80M |
| September 30, 2022 | 32.88M |
| June 30, 2022 | 33.23M |
| March 31, 2022 | 37.80M |
| December 31, 2021 | 25.07M |
| September 30, 2021 | 32.97M |
| June 30, 2021 | 24.86M |
| March 31, 2021 | 13.53M |
| December 31, 2020 | 12.78M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 208.15M |
| Shareholders Equity (Quarterly) | 126.13M |
| Debt to Equity Ratio | 0.3926 |
| Current Ratio | 16.09 |
| Net Debt Paydown Yield | -0.98% |